PUBLISHER: The Business Research Company | PRODUCT CODE: 1945268
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945268
Heart block treatment devices encompass medical instruments designed to address and correct disruptions in the heart's electrical conduction system, particularly heart block conditions. These devices play a crucial role in regulating the heart's rhythm and ensuring the proper coordination of electrical signals between its chambers, namely the atria and ventricles.
Heart block treatment devices come in various types, including first-degree heart block, second-degree heart block, and third-degree heart block. First-degree heart block refers to a conduction abnormality characterized by a delay in the transmission of electrical signals through the heart's atrioventricular (AV) node. In cases of first-degree heart block, the deployment of a pacemaker is typically reserved for rare instances where the blockage significantly impacts the individual's quality of life or if there are indications of progression to higher degrees of heart block. The diverse array of products within heart block treatment devices includes transcutaneous pacing (TCP), pacemaker, medication, and follow-up electrophysiology study. These devices find application in hospital testing, home treatment, clinics, and various other settings.
Tariffs are impacting the heart blocks treatment devices market by increasing the cost of imported electronic components, medical-grade metals, batteries, and precision manufacturing equipment used in pacemakers, ICDs, and CRT devices. Hospitals and device manufacturers in North America and Europe are most affected due to reliance on cross-border sourcing of critical components, while Asia-Pacific faces higher production costs for export-oriented device manufacturing. These tariffs are increasing overall device pricing and procurement budgets for healthcare providers. However, they are also encouraging localized device manufacturing, regional supplier diversification, and long-term investments in domestic medical device production capabilities.
The heart blocks treatment devices market research report is one of a series of new reports from The Business Research Company that provides heart blocks treatment devices market statistics, including heart blocks treatment devices industry global market size, regional shares, competitors with a heart blocks treatment devices market share, detailed heart blocks treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the heart blocks treatment devices industry. This heart blocks treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The heart blocks treatment devices market size has grown strongly in recent years. It will grow from $3.36 billion in 2025 to $3.59 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising prevalence of cardiovascular disorders, increasing aging population, expansion of hospital cardiac care infrastructure, improved access to cardiac diagnostic services, advancements in implantable device reliability.
The heart blocks treatment devices market size is expected to see strong growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing adoption of remote patient monitoring, rising investments in cardiac digital health solutions, increasing demand for personalized rhythm management, expansion of home-based cardiac care models, continuous innovation in implantable cardiac devices. Major trends in the forecast period include increasing adoption of advanced pacemaker technologies, rising use of implantable cardiac rhythm devices, growing integration of remote cardiac monitoring systems, expansion of minimally invasive cardiac procedures, enhanced focus on long-term rhythm management.
The increasing prevalence of cardiovascular disease is expected to drive the growth of the heart blocks treatment devices market in the coming years. Cardiovascular diseases, which affect the heart and blood vessels, include conditions such as coronary artery disease, heart failure, and stroke. The rising incidence of cardiovascular disease is largely attributed to an aging population, lifestyle and dietary changes, as well as growing rates of obesity and diabetes. Heart blocks treatment devices are used to address cardiovascular disorders by correcting abnormalities or defects in the heart's structures and electrical pathways. For example, in March 2024, GOV.UK, a UK-based government information provider, reported that in the financial year ending in 2023, slightly over 1,862,500 people in England, or 3% of the population, had a GP diagnosis of coronary heart disease (CHD). As a result, the growing prevalence of cardiovascular disease is boosting the demand for heart blocks treatment devices.
The growing size of the aging population is expected to drive the growth of the heart block treatment device market. An aging population refers to a demographic trend in which the proportion of older individuals steadily increases. As people age, the risk of developing cardiac conduction abnormalities, such as heart block, rises, creating greater demand for treatment devices. For example, in July 2024, the UK Parliament's House of Commons Library, a UK-based government body, reported that in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to increase to 22.1 million by 2072, accounting for 27% of the population. Consequently, the expanding aging population is expected to fuel demand for heart block treatment devices.
Prominent companies in the heart block treatment device market are concentrating on technological advancements, exemplified by the development of dual-chamber pacemakers to ensure reliable services for customers. Dual-chamber pacemakers encompass leadless pacing systems designed to address abnormal or slow heart rhythms. In a notable example from November 2023, Abbott Laboratories, a multinational medical device and healthcare company based in the United States, introduced a dual-chamber pacemaker, marking its first U.S. implants. Recognizing that over 80% of individuals requiring a pacemaker need pacing in two heart chambers-the right atrium and right ventricle-Abbott Laboratories incorporated i2i technology. This innovation employs high-frequency pulses to convey messages through the body's naturally conductive characteristics, establishing communication between each leadless pacemaker.
Major companies operating in the heart blocks treatment devices market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, MicroPort Scientific Corporation, Lepu Medical Technology (Beijing) Co. Ltd., Nihon Kohden Corporation, ZOLL Medical Corporation, LivaNova PLC, Osypka Medical GmbH, Shree Pacetronix Ltd., EBR Systems Inc., Medico S.p.A., Cook Medical, B. Braun SE, Oscor Inc., Pacetronix Ltd., Fukuda Denshi Co. Ltd., Teleflex Incorporated, NIPRO Corporation
North America was the largest region in the heart blocks treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heart blocks treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the heart blocks treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The heart blocks treatment devices market consists of sales of implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and leadless pacemakers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Heart Blocks Treatment Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses heart blocks treatment devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for heart blocks treatment devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The heart blocks treatment devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.